Baillie Gifford & Co
BEAM icon

Baillie Gifford & Co’s Beam Therapeutics BEAM Stock Holding History

Baillie Gifford & Co’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Sell
314,228
-71,663
-19% -$2.16M 0.01% 197
2026
Q1 		$9.2M Sell
385,891
-30,333
-7% -$842K 0.01% 213
2025
Q4 		$11.5M Buy
416,224
+118,421
+40% +$3.02M 0.01% 215
2025
Q3 		$7.23M Sell
297,803
-2,334
-0.8% -$46.4K 0.01% 229
2025
Q2 		$5.11M Sell
300,137
-2,597
-0.9% -$45.2K ﹤0.01% 225
2025
Q1 		$5.91M Sell
302,734
-5,502
-2% -$144K 0.01% 226
2024
Q4 		$7.64M Sell
308,236
-49,462
-14% -$1.26M 0.01% 216
2024
Q3 		$8.76M Sell
357,698
-265,942
-43% -$6.87M 0.01% 217
2024
Q2 		$14.6M Sell
623,640
-128,754
-17% -$3.16M 0.01% 194
2024
Q1 		$24.9M Sell
752,394
-11,729
-2% -$365K 0.02% 181
2023
Q4 		$20.8M Sell
764,123
-111,624
-13% -$2.77M 0.02% 189
2023
Q3 		$21.1M Buy
875,747
+352,014
+67% +$9.44M 0.02% 182
2023
Q2 		$16.7M Buy
523,733
+70,972
+16% +$2.3M 0.01% 189
2023
Q1 		$13.9M Sell
452,761
-2,067
-0.5% -$81.6K 0.01% 203
2022
Q4 		$17.8M Buy
454,828
+69,610
+18% +$3.12M 0.02% 191
2022
Q3 		$18.4M Buy
385,218
+374,545
+3,509% +$21.4M 0.02% 191
2022
Q2 		$413K Hold
10,673
– – ﹤0.01% 287
2022
Q1 		$612K Hold
10,673
– – ﹤0.01% 283
2021
Q4 		$851K Sell
10,673
-27
-0.3% -$2.31K ﹤0.01% 282
2021
Q3 		$931K Buy
10,700
+10,213
+2,097% +$1.03M ﹤0.01% 275
2021
Q2 		$63K Sell
487
-32
-6% -$2.55K ﹤0.01% 283
2021
Q1 		$42K Buy
519
+24
+5% +$2.28K ﹤0.01% 287
2020
Q4 		$40K Buy
+495
New +$24.3K ﹤0.01% 279

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Baillie Gifford & Co's BEAM Position: Q2 2026 in Review

Baillie Gifford & Co reduced its Beam Therapeutics (BEAM) stake by 19% in Q2 2026, selling an estimated $2.16M and leaving 314,228 shares worth $10.8M. The position accounts for 0.01% of the portfolio, ranked #197.

Baillie Gifford & Co first reported a position in BEAM in Q4 2020 and has held it in 23 quarters since. The position peaked at $24.9M in Q1 2024. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Baillie Gifford & Co held 314,228 shares of Beam Therapeutics worth $10.8M as of Q2 2026.
  • Baillie Gifford & Co sold 71,663 Beam Therapeutics shares in Q2 2026, an estimated $2.16M.
  • Beam Therapeutics made up 0.01% of Baillie Gifford & Co's portfolio in Q2 2026, its #197 holding.
  • Baillie Gifford & Co first reported a position in Beam Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Baillie Gifford & Co's Beam Therapeutics position peaked at $24.9M in Q1 2024.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.